<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611790</url>
  </required_header>
  <id_info>
    <org_study_id>VS-002 / D</org_study_id>
    <nct_id>NCT03611790</nct_id>
  </id_info>
  <brief_title>Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)</brief_title>
  <official_title>The Vesalio Neva VS for the Treatment of Symptomatic Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage (aSAH) (The VITAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vesalio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vesalio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety and probable benefit of the Neva VS device
      in patients presenting with symptomatic cerebral vasospasm despite maximal medical management
      following aSAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, single-arm study. Up to 30 eligible subjects at up to 15
      sites will participate in the study. Subjects will be followed up for 30 days
      post-intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>within 30 minutes of completion of procedure</time_frame>
    <description>defined as 50% or greater vessel caliber on DSA compared to baseline, as determined by the core laboratory</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeVa VS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeVa VS</intervention_name>
    <description>mechanical dilatation</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age ≥ 18 years.

          -  Subarachnoid hemorrhage secondary to ruptured aneurysm.

          -  Ruptured aneurysm secured with surgical clipping or endovascular intervention.

          -  Digital subtraction angiography (DSA) or CT angiography at the time of aSAH clinical
             presentation or aSAH intervention with well-visualized intra-cerebral vessels is
             available for review.

          -  Vasospasm in one or more of the following: the internal carotid artery (ICA), basilar,
             middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral
             artery (PCA) territory on transcranial Doppler (TCD), and/or CT angiography, and/or
             clinical signs of symptomatic vasospasm (change in level of consciousness, focal
             neurological deficit) confirmed by &gt; 50% narrowing in these territories on DSA.

          -  Vasospasm despite maximized medical management defined as oral Nimodipine (unless
             contraindicated), systemic hypertension with SBP greater than 130 mmHg and euvolemia.

          -  Target vessel pre-vasospasm diameter ≥ 2 mm and ≤ 4.0 mm.

          -  Subject or legal representative is able and willing to give informed consent.

        Exclusion Criteria

          -  The presence of an unsecured ruptured aneurysm. Note unsecured unruptured aneurysms
             remote to the site of treated aSAH are not an exclusionary.

          -  Symptoms attributable to other causes (e.g., hydrocephalus, metabolic, infection).

          -  Hunt and Hess Grade of 5

          -  Large infarct on CT scan defined as ASPECTS 0-5.

          -  Intracranial hemorrhage not caused by aneurysm rupture.

          -  History of bleeding disorders.

          -  Baseline platelets &lt; 30,000.

          -  International normalized ratio (INR) &gt; 1.7.

          -  Any known contraindications to mechanical dilation of vasospastic vessels including
             but not limited to:

          -  Excessive vessel tortuosity that prevents the placement of the device

          -  Evidence of rapidly improving neurological signs of stroke

          -  Large territory completed cerebral infarction, edema with mass effect and
             intra-parenchymal hemorrhage in vascular territory to be treated, or

          -  any other vascular anatomic variants or anomalies

          -  Pre-existing neurological or psychiatric disease that would confound the neurological
             or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor
             (e.g. Aricept).

          -  History of severe allergy to contrast medium.

          -  Known allergy to NeVa materials (nitinol, stainless steel).

          -  Suspected or confirmed septic embolus, or bacterial endocarditis.

          -  Septic shock or central nervous system (CNS) infection confirmed via cerebrospinal
             fluid (CSF) sampling.

          -  Known current or recent use of illicit drugs or alcohol abuse.

          -  Females who are pregnant or breastfeeding.

          -  Any other condition that, in the opinion of the investigator, precludes an
             endovascular procedure or poses a significant hazard to the subject if an endovascular
             procedure is performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen Calderon</last_name>
    <phone>615-206-7788</phone>
    <email>kcalderon@vesalio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RIA Neurovascular Clinic</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Gottschlich</last_name>
      <phone>720-493-3403</phone>
      <email>Melissa.Gottschlich@riaco.com</email>
    </contact>
    <investigator>
      <last_name>Don Frei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health System</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ebreo</last_name>
      <phone>904-202-7063</phone>
    </contact>
    <investigator>
      <last_name>Ricardo A Hanel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellstar Health System</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Diaz</last_name>
      <email>gabriella.diaz@wellstar.org</email>
    </contact>
    <investigator>
      <last_name>Rishi Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Smith</last_name>
      <email>ssmith@ubns.org</email>
    </contact>
    <investigator>
      <last_name>Adnan H Siddiqui, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital - Northwell</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Moclair, RN, CCRC</last_name>
      <phone>516-253-7753</phone>
      <email>bmoclair@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Adams</last_name>
      <phone>212-241-8349</phone>
      <email>Ryan.Adams@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Reade De Leacy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Baumeister, BSN</last_name>
      <phone>631-444-1610</phone>
      <email>marlene.baumeister@sbumed.org</email>
    </contact>
    <investigator>
      <last_name>David Fiorella, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Sanders Regional Med Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Ogle</last_name>
      <phone>865-247-6968</phone>
    </contact>
    <investigator>
      <last_name>Keith Woodward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TTUHSC El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israel Alba</last_name>
      <phone>915-215-4616</phone>
      <email>israel.alba@ttuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Alberto Maud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ibarra Cortez</last_name>
      <phone>713-441-3248</phone>
      <email>sibarra@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Orlando Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Kluznik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

